My Treatment Approach: Advancing Treatment Strategies for HER2+ Metastatic Breast Cancer - Episode 4
The Impact of Trastuzumab Deruxtecan on Clinical Practice for HER2+ Advanced BC and Brain Mets
Panelists discuss how the DESTINY-Breast12 trial has influenced their approach to using trastuzumab deruxtecan (T-DXd) for patients with HER2-positive advanced breast cancer with brain metastases, highlighting the patient subgroups most likely to benefit from T-DXd and its impact on treatment sequencing for those with active brain metastases.
Video Player is loading.
Video content above is prompted by the following:
- How has the DESTINY-Breast12 trial impacted your view on using T-DXd for patients with HER2-positive advanced breast cancer and brain metastases?
- Which patient subgroups are most likely to benefit from T-DXd, and how do these data influence treatment sequencing for those with active brain metastases?
Related Content:
